title: Valsartan-induced hepatotoxicity in a HBs-Ag-Positive patient.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Kiykim
authors.forename: Engin
authors.initials: E
authors.lastname: Altintas
authors.forename: Orhan
authors.initials: O
authors.lastname: Sezgin
authors.forename: Kerem
authors.initials: K
authors.lastname: Sezer
authors.forename: Naci
authors.initials: N
authors.lastname: Tiftik
authors.forename: Esen
authors.initials: E
authors.lastname: Akbay
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Seyrek
authors.forename: Kamuran
authors.initials: K
authors.lastname: Konca
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D006514:Hepatitis B Surface Antigens; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008875:Middle Aged; D013777:Tetrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D014633:Valine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D000959:Antihypertensive Agents; D006514:Hepatitis B Surface Antigens; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine